Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 110806263
Gene Symbol: LOC110806263
LOC110806263
0.100 GeneticVariation group BEFREE In FTC, TERT promoter mutations were significantly associated with age, distant metastases, advanced TNM stage, persistence/recurrence, and disease-specific mortality. 31655978 2020
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 Biomarker group BEFREE The purpose of this study is to prospectively evaluate the performance of sodium <sup>18</sup>F]fluoride (Na[<sup>18</sup>F]F)/2-deoxy-2-[<sup>18</sup>F]fluoro-D-glucose ([<sup>18</sup>F]FDG) simultaneous time-of-flight enabled positron emission tomography (PET)/magnetic resonance imaging (MRI) for the detection of skeletal metastases in selected patients with advanced breast and prostate cancers. 31236756 2020
Entrez Id: 4313
Gene Symbol: MMP2
MMP2
0.100 Biomarker group BEFREE In ATAT for the group of patients with distant metastasis (M1) the superoxide generation rate, MMP-2, 9 activities are about 2 times higher (p < 0.05) than in the subgroup without distant metastases (M0). 31711773 2020
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation group BEFREE It has been recently shown that mutant p53 proteins mediate metabolic changes thereby promoting cancer development and metastases. 31112799 2020
Entrez Id: 5743
Gene Symbol: PTGS2
PTGS2
0.100 AlteredExpression group BEFREE COX-2 level is significantly lower in nevi than in melanomas, increases gradually with progression of these malignant cancers and reaches the highest values in metastases. 31675116 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.100 AlteredExpression group BEFREE The high prostate-specific membrane antigen expression in prostate cancer metastases makes it a promising approach for targeted radionuclide therapy of prostate cancer. 31162261 2020
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.100 Biomarker group BEFREE Comparison of <sup>18</sup>F-FDG PET/MRI, MRI, and <sup>18</sup>F-FDG PET/CT for the detection of synchronous cancers and distant metastases in patients with oropharyngeal and hypopharyngeal squamous cell carcinoma. 31606831 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.100 Biomarker group BEFREE Positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) is a promising technique that outperformed conventional imaging in the detection of nodal and distant metastases in previous studies. 31802175 2020
Entrez Id: 4318
Gene Symbol: MMP9
MMP9
0.100 Biomarker group BEFREE Mechanistically, we found that the phosphatidylinositol 3-kinase-AKT signal pathway and its downstream effectors, such as tissue inhibitor of metalloproteinases 1 and matrix metallopeptidase 9, were required for MUC13-mediated tumor metastasis of iCCA. 31837357 2020
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.100 Biomarker group BEFREE In the multivariate analysis, the Gleason score, PSA and presence of metastases were associated with shorter OS and PFS. 29891440 2020
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.100 Biomarker group BEFREE Ga-PSMA PET/CT has become a well-established imaging modality to detect prostate cancer (PCa) metastases in biochemical recurrence. 31306199 2020
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.100 AlteredExpression group BEFREE We identified that BRAF-activated noncoding RNA was upregulated in pancreatic cancer tissues and cell lines, and BRAF-activated noncoding RNA was related to tumor metastasis and stage. 31769353 2020
Entrez Id: 6696
Gene Symbol: SPP1
SPP1
0.100 AlteredExpression group BEFREE It may be noted that despite being a strong marker to identify human tumor metastasis, no study on effect of artemisinin and its synthetic and semisynthetic derivatives on OPN expression has ever been studied. 31791643 2020
Entrez Id: 7076
Gene Symbol: TIMP1
TIMP1
0.100 Biomarker group BEFREE Mechanistically, we found that the phosphatidylinositol 3-kinase-AKT signal pathway and its downstream effectors, such as tissue inhibitor of metalloproteinases 1 and matrix metallopeptidase 9, were required for MUC13-mediated tumor metastasis of iCCA. 31837357 2020
Entrez Id: 7076
Gene Symbol: TIMP1
TIMP1
0.100 AlteredExpression group BEFREE Elevated expression of MMP-1 and TIMP-1 in tumour tissue can be considered a predictive factor for the development of metastases. 31646745 2020
Entrez Id: 2625
Gene Symbol: GATA3
GATA3
0.100 Biomarker group BEFREE Using both GATA3 and SOX10 is recommended for confirming breast as the site of origin in metastases that lack estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression, whereas the addition of AR is not helpful. 30468800 2019
Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
0.100 AlteredExpression group BEFREE A decreased overall survival was significantly associated with peritoneal involvement (HR 1.944; p = 0.003), ascites (HR 2.055; p = 0.034), synchronous presentation (HR 1.679; p = 0.034) and increased serum CEA levels (HR 1.380; p = 0.010), but not with age > 50 (HR 0.946; p = 0.743), menopausal status (HR 1.565; p = 0.204), gastric origin (HR 1.600; p = 0.201), size > 5 cm (HR 1.292; p = 0.119), size > 10 cm (HR 0.925; p = 0.714), bilateral ovarian involvement (HR 1.113; p = 0.347), non-peritoneal extaovarian metastases (HR 1.648; p = 0.237), liver metastases (HR 1.118, p = 0.555), predominant signet ring cell morphology (HR 1.322; p = 0.208) and levels of CA125 (HR 0.933; p = 0.828) and CA19.9 (HR 0.996; p = 0.992). 31542818 2019
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 Biomarker group BEFREE The median time between diagnosis and IBM was 46.7 months (range 0-180).Most CRC metastases are CK7-/CK20+. 31087546 2019
Entrez Id: 6624
Gene Symbol: FSCN1
FSCN1
0.100 Biomarker group BEFREE Inhibition of fascin ex vivo blocked OvCa cell colonization of human omental tissue and in vivo prevented and reduced OvCa metastases in mice. 30797592 2019
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.100 AlteredExpression group BEFREE Ga-PSMA expression in fibrous dysplasia should not automatically be equated with malignant transformation or confused with prostate cancer metastases. 31058693 2019
Entrez Id: 110806263
Gene Symbol: LOC110806263
LOC110806263
0.100 GeneticVariation group BEFREE TERT promoter mutation- (OR: 40.58; 95% CI: 3.06-539.04), and N1b lymph node metastases (OR: 40.16, 95% CI: 3.48-463.04) were independent predictors of distant metastases. 31042674 2019
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker group BEFREE The results of this study showed that RFA is a safe and locally effective method for the treatment of BCLM, especially in patients with lesions measuring less than 3 cm in diameter, a single liver metastasis, positive estrogen receptor status and no extrahepatic metastases. 30200791 2019
Entrez Id: 1084
Gene Symbol: CEACAM3
CEACAM3
0.100 Biomarker group BEFREE Univariate logistic regression analysis showed that CEA (OR 1.056, 95% CI 1.007-1.107, p = 0.02) was the only preoperative predictor for occult metastases. 31186205 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.100 GeneticVariation group BEFREE The incidence of the three MAF variants in BRAF-mutant primaries was similar, whereas the high MAF cases were found to be increased in metastases. 31391014 2019
Entrez Id: 1087
Gene Symbol: CEACAM7
CEACAM7
0.100 Biomarker group BEFREE Univariate logistic regression analysis showed that CEA (OR 1.056, 95% CI 1.007-1.107, p = 0.02) was the only preoperative predictor for occult metastases. 31186205 2019